Key Highlights

  • The net loss for the third quarter of 2026 was $32.4 million.
  • Research and development expenses reached $26.1 million for the quarter.
  • Cash, cash equivalents and short-term investments were about $202 million at September 30, 2026.
  • General and administrative expenses were $8.3 million for the quarter.

Perspective Therapeutics, Inc. The Seattle-based radiopharmaceutical developer, which is building targeted cancer treatments that deliver Alpha radiation, also reported cash, cash equivalents and short-term investments of about $202 million.

Research Spending and Operating Costs

Research and development expenses reached $26.1 million for the quarter, up from a year earlier. For a clinical-stage company, that line is the largest driver of losses, because it covers trial enrollment, manufacturing, drug Supply and the personnel needed to run studies.

Radiopharmaceuticals combine a targeting molecule with a radioactive isotope, and Manufacturing them requires specialized facilities and supply chains. Alpha-emitting isotopes release high-energy particles over a short distance, which the company believes can destroy cancer cells while limiting damage to surrounding tissue.

Cash Position and Funding

Cash, cash equivalents and short-term investments stood at approximately $202 million at September 30, 2026, compared with about $145 million at December 31, 2025.

Final Word

Perspective Therapeutics' third quarter shows a net loss of $32.4 million, research spending of $26.1 million and about $202 million in cash and investments. The figures describe a company funding clinical development through its cash balance.